Ipsen and Exelixis to host joint investor briefing on Phase 3 CELESTIAL trial results presented at ASCO GI

Ipsen and its partner Exelixis will jointly host a live investor briefing at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) on the results of the Phase 3 CELESTIAL trial for Cabometyx in advanced hepatocellular carcinoma (HCC).

During the briefing, Exelixis and Ipsen management, along with special guest Dr. Katie Kelley of UCSF, will discuss and provide context for the cabozantinib clinical data presented earlier that day at the Symposium. CELESTIAL is a randomized, double-blind, placebo-controlled study of cabozantinib versus placebo in patients with HCC who have received prior treatment with sorafenib.

To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading.

Alternatively, please call +1 (855)-793-2457 (domestic) or +1 (631)-485-4921 (international) and provide the conference call passcode 2478857 to join by phone.

Date:  Friday, January 19, 2018
Time:    Presentation and webcast – 6:30pm PST (local time, San Francisco) / 9:30pm EST


Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast.


A webcast replay will be archived on www.exelixis.com for one year.

A telephone replay will also be available until 11h59 p.m. EST on January 26, 2018. Access numbers for the telephone replay are: +1 (855)-859-2056 (domestic) and +1 (404)-537-3406 (international); the passcode is 2478857.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2021